CCT365623 hydrochloride

Name: CCT365623 hydrochloride
Brand: TargetMol
SKU: T10719
Rating: 4.5 (1 reviews)

还可以

产品编号 T10719Cas号 2126136-98-7

CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.

CCT365623 hydrochloride

还可以

产品编号 T10719Cas号 2126136-98-7

CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.

规格	价格	库存
25 mg	¥ 12,800	1-2周
50 mg	¥ 16,800	1-2周
100 mg	¥ 21,500	1-2周

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

CCT365623 hydrochloride 相关产品

产品介绍

生物活性

产品描述	CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.
靶点活性	LOX:0.89 μM
体外活性	CCT365623 inhibits LOX at ~5 μM in the biosensor system. CCT365623 (0-40 μM) concentration-dependently decreases the protein levels of surface EGFR. CCT365623 disrupts HTRA1 multimerization, activates TGFβ1 signaling, suppresses MATN2 expression, suppresses EGFR surface retention, and suppresses EGFR signaling. CCT365623 (5 μM) decreases the protein levels of pY1068 EGFR, pAKT, and MATN2, and increases the protein levels of pSMAD2.
体内活性	CCT365623 (70 mg/kg, oral gavage per day) significantly delays the development of the primary tumors and also suppresses metastatic lung burden in the animals. CCT365623 disrupts EGFR cell surface retention and delays the growth of primary and metastatic tumor cells. CCT365623 exhibits a T1/2PO of 0.6 h and F% (oral bioavailability) of 45%.